NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
11 juil. 2024 07h00 HE | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline
11 juil. 2024 01h00 HE | NMD Pharma
NMD Pharma adds new capabilities with several senior recruits to support its growing business and pipeline Aarhus, Denmark, 11 July 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
18 juin 2024 07h00 HE | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US
18 juin 2024 01h00 HE | NMD Pharma
NMD Pharma Receives IND Clearance from the FDA to initiate a Phase 2 Clinical Trial of NMD670 in Charcot-Marie-Tooth disease in the US Aarhus, Denmark, 18 June 2024 – NMD Pharma A/S, a clinical-stage...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 06h00 HE | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing novel...
NMD_Logo3_reg.jpg
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients
11 juin 2024 01h00 HE | NMD Pharma
NMD Pharma Initiates Phase 2b Trial of NMD670 in Generalized Myasthenia Gravis Patients Aarhus, Denmark, 11 June 2024 – NMD Pharma A/S, a clinical-stage biotech company dedicated to developing...
NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22 mars 2024 07h00 HE | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US
22 mars 2024 02h00 HE | NMD Pharma
NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US Aarhus, Denmark, 22 March 2024 – NMD Pharma A/S, a...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21 mars 2024 07h00 HE | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...
NMD_Logo3_reg.jpg
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine
21 mars 2024 02h00 HE | NMD Pharma
NMD Pharma Publishes Comprehensive Data Package for NMD670 in Science Translational Medicine ClC-1 is a chloride ion channel specifically expressed in skeletal muscle cells that normally dampens...